NICE recommends new treatment for highly active relapsing multiple sclerosis
Abstract
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment option for adults with highly active relapsing-remitting multiple sclerosis (RRMS) for use on the NHS in England. In final guidance, published on 2 January 2025, NICE approved natalizumab, a monoclonal antibody that can be given by injection or infusion, for adults with […]
Fields of Study & Subjects
Multiple Sclerosis Research Studies
Healthcare Systems and Challenges
Peripheral Neuropathies and Disorders
Publication details
- Journal / source
- Pharmaceutical journal/The pharmaceutical journal
- Publication date
- 1 January 2026